NCT01045720

Brief Summary

The goal of this research is hoping to combine traditional Chinese medicine medication and find out how to solve clozapine-induced hypersalivation, also reduce side-effect, medication compliance, improving life quality, improving social-function and reducing neopathy.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
45

participants targeted

Target at P25-P50 for phase_2 schizophrenia

Timeline
Completed

Started Jan 2010

Shorter than P25 for phase_2 schizophrenia

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2010

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

January 5, 2010

Completed
6 days until next milestone

First Posted

Study publicly available on registry

January 11, 2010

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2010

Completed
Last Updated

January 14, 2010

Status Verified

January 1, 2010

Enrollment Period

2 months

First QC Date

January 5, 2010

Last Update Submit

January 13, 2010

Conditions

Keywords

SchizophreniaclozapinehypersalivationSuo Quan WanWu Lin San

Study Arms (2)

Placebo Comparator

PLACEBO COMPARATOR
Drug: Placebo

ChinesMed

EXPERIMENTAL
Drug: Suo Quan Wan, Wu Lin San

Interventions

Suo Quan Wan Wu Lin San Placebo 2/daily

ChinesMed

Placebo (starch)

Placebo Comparator

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • year and older. All genders. 2.Psychiatry doctor diagnosed schizophrenia or schizoaffective disorder will be recruited for participation in this study.
  • Using clozapine as an antipsychotic drug and has a side-effect of hypersalivation.
  • Testee agree and sign informed consent forms to do this experiment.

You may not qualify if:

  • Use clozapine as an antipsychotic drug not over 8 weeks.
  • Testee have other diseases could influence saliva secretion, such as Parkinson's disease.
  • Pregnant, prepare to pregnant within half a year or in the lactation period.
  • Add or alter following medicines within 2 weeks:
  • Central acting 2-adrenergic receptor agonist 4.2 anticholinergic/antimuscarinic drugs 4.3 b-adrenoreceptor blockers, diphenhydramine, botulinum toxin injection
  • Testee's lever function test (AST/ALT) is higher than 3 (4 weeks medication).
  • Testee's kidney function test (Cr) is higher than 2.5mg/dl (4 weeks medication).
  • Testee have participate other medicine trial within one month.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Taichung Veterans General Hospital

Taichung, Taiwan, 40705, Taiwan

RECRUITING

Related Publications (1)

  • Hung CC, Fu PK, Wang HY, Chan CH, Lan TH. Treatment effects of traditional Chinese medicines Suoquan Pill and Wuling Powder on clozapine-induced hypersalivation in patients with schizophrenia: study protocol of a randomized, placebo-controlled trial. Zhong Xi Yi Jie He Xue Bao. 2011 May;9(5):495-502.

MeSH Terms

Conditions

SchizophreniaSialorrhea

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental DisordersSalivary Gland DiseasesMouth DiseasesStomatognathic Diseases

Study Officials

  • Tsuo-Hung Lan, MD., PhD.

    Taichung Veterans General Hospital

    STUDY DIRECTOR
  • Tsuo-Hung Lan, MD.,PhD

    Taichung Veterans General Hospital

    STUDY DIRECTOR

Central Study Contacts

Tsuo-Hung Lan, MD., PhD.

CONTACT

Chia-Chun Hung, MD.

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

January 5, 2010

First Posted

January 11, 2010

Study Start

January 1, 2010

Primary Completion

March 1, 2010

Study Completion

March 1, 2010

Last Updated

January 14, 2010

Record last verified: 2010-01

Locations